By Anthony O. Goriainoff

AstraZeneca PLC said Monday that its Forxiga drug has been approved in China for the treatment of chronic kidney disease, or CKD, in patients at risk of progression with and without type-2 diabetes.

The Anglo-Swedish pharma giant said the approval was based on positive results from the DAPA-CKD phase 3 trial.

The company said that Forxiga, also known as Farxiga in the U.S., was now approved in 100 countries around the world including the U.S., the EU and Japan for the treatment of chronic kidney disease in adults with and without T2D.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

September 05, 2022 02:40 ET (06:40 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more AstraZeneca Charts.